Dale S Cannon1, Tait R Medina2, Robin J Mermelstein3, Donald Hedeker4, Amanda V Bakian5, Hilary Coon5, Edwin H Cook6, Cindy Hamil7, Robert B Weiss7. 1. Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, UT; dale.cannon@hsc.utah.edu. 2. Department of Sociology, Indiana University, Bloomington, IN; Institute for Health Research and Policy, University of Illinois, Chicago, IL; 3. Institute for Health Research and Policy and Psychology Department, University of Illinois, Chicago, IL; 4. Department of Health Sciences, University of Chicago, Chicago, IL; 5. Department of Psychiatry, University of Utah School of Medicine, Salt Lake City, UT; 6. Institute for Juvenile Research, Department of Psychiatry, University of Illinois, Chicago, IL; 7. Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, UT.
Abstract
INTRODUCTION: The present study sought to identify time-dependent within-participant effects of CYP2A6 genotypes on smoking frequency and nicotine dependence in young smokers. METHODS: Predicted nicotine metabolic rate based on CYP2A6 diplotypes (CYP2A6 diplotype predicted rate [CDPR]) was partitioned into Normal, Intermediate, and Slow categories using a metabolism metric. Growth-curve models characterized baseline and longitudinal CDPR effects with data from eight longitudinal assessments during a 6-year period (from approximately age 16-22) in young smokers of European descent (N = 296, 57% female) who had smoked less than 100 cigarettes lifetime at baseline and more than that amount by Year 6. Phenotypes were number of days smoked during the previous 30 days and a youth version of the Nicotine Dependence Syndrome Scale (NDSS). A zero-inflated Poisson growth-curve model was used to account for the preponderance of zero days smoked. RESULTS: At baseline, Intermediate CDPR was a risk factor relative to both Normal and Slow CDPR for smoking frequency and the NDSS. Slow CDPR was associated with the highest probability of smoking discontinuation at baseline. However, due to CDPR time trend differences, by young adulthood these baseline effects had been reordered such that the greatest risks for smoking frequency and the NDSS were associated with Normal CDPR. CONCLUSIONS: Reduced metabolism CYP2A6 genotypes are associated with both risk and protective effects in novice smokers. However, differences in the time-by-CDPR effects result in a reordering of genotype effects such that normal metabolism becomes the risk variant by young adulthood, as has been reliably reported in older smokers.
INTRODUCTION: The present study sought to identify time-dependent within-participant effects of CYP2A6 genotypes on smoking frequency and nicotine dependence in young smokers. METHODS: Predicted nicotine metabolic rate based on CYP2A6 diplotypes (CYP2A6 diplotype predicted rate [CDPR]) was partitioned into Normal, Intermediate, and Slow categories using a metabolism metric. Growth-curve models characterized baseline and longitudinal CDPR effects with data from eight longitudinal assessments during a 6-year period (from approximately age 16-22) in young smokers of European descent (N = 296, 57% female) who had smoked less than 100 cigarettes lifetime at baseline and more than that amount by Year 6. Phenotypes were number of days smoked during the previous 30 days and a youth version of the Nicotine Dependence Syndrome Scale (NDSS). A zero-inflated Poisson growth-curve model was used to account for the preponderance of zero days smoked. RESULTS: At baseline, Intermediate CDPR was a risk factor relative to both Normal and Slow CDPR for smoking frequency and the NDSS. Slow CDPR was associated with the highest probability of smoking discontinuation at baseline. However, due to CDPR time trend differences, by young adulthood these baseline effects had been reordered such that the greatest risks for smoking frequency and the NDSS were associated with Normal CDPR. CONCLUSIONS: Reduced metabolism CYP2A6 genotypes are associated with both risk and protective effects in novice smokers. However, differences in the time-by-CDPR effects result in a reordering of genotype effects such that normal metabolism becomes the risk variant by young adulthood, as has been reliably reported in older smokers.
Authors: Amanda R Mathew; Amy E Wahlquist; Elizabeth Garrett-Mayer; Kevin M Gray; Michael E Saladin; Matthew J Carpenter Journal: Nicotine Tob Res Date: 2014-06-12 Impact factor: 4.244
Authors: Joseph Bloom; Anthony L Hinrichs; Jen C Wang; Linda B von Weymarn; Evan D Kharasch; Laura J Bierut; Alison Goate; Sharon E Murphy Journal: Pharmacogenet Genomics Date: 2011-07 Impact factor: 2.089
Authors: Thorgeir E Thorgeirsson; Daniel F Gudbjartsson; Ida Surakka; Jacqueline M Vink; Najaf Amin; Frank Geller; Patrick Sulem; Thorunn Rafnar; Tõnu Esko; Stefan Walter; Christian Gieger; Rajesh Rawal; Massimo Mangino; Inga Prokopenko; Reedik Mägi; Kaisu Keskitalo; Iris H Gudjonsdottir; Solveig Gretarsdottir; Hreinn Stefansson; John R Thompson; Yurii S Aulchenko; Mari Nelis; Katja K Aben; Martin den Heijer; Asger Dirksen; Haseem Ashraf; Nicole Soranzo; Ana M Valdes; Claire Steves; André G Uitterlinden; Albert Hofman; Anke Tönjes; Peter Kovacs; Jouke Jan Hottenga; Gonneke Willemsen; Nicole Vogelzangs; Angela Döring; Norbert Dahmen; Barbara Nitz; Michele L Pergadia; Berta Saez; Veronica De Diego; Victoria Lezcano; Maria D Garcia-Prats; Samuli Ripatti; Markus Perola; Johannes Kettunen; Anna-Liisa Hartikainen; Anneli Pouta; Jaana Laitinen; Matti Isohanni; Shen Huei-Yi; Maxine Allen; Maria Krestyaninova; Alistair S Hall; Gregory T Jones; Andre M van Rij; Thomas Mueller; Benjamin Dieplinger; Meinhard Haltmayer; Steinn Jonsson; Stefan E Matthiasson; Hogni Oskarsson; Thorarinn Tyrfingsson; Lambertus A Kiemeney; Jose I Mayordomo; Jes S Lindholt; Jesper Holst Pedersen; Wilbur A Franklin; Holly Wolf; Grant W Montgomery; Andrew C Heath; Nicholas G Martin; Pamela A F Madden; Ina Giegling; Dan Rujescu; Marjo-Riitta Järvelin; Veikko Salomaa; Michael Stumvoll; Tim D Spector; H-Erich Wichmann; Andres Metspalu; Nilesh J Samani; Brenda W Penninx; Ben A Oostra; Dorret I Boomsma; Henning Tiemeier; Cornelia M van Duijn; Jaakko Kaprio; Jeffrey R Gulcher; Mark I McCarthy; Leena Peltonen; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nat Genet Date: 2010-04-25 Impact factor: 38.330
Authors: Santiago Rodriguez; Derek G Cook; Tom R Gaunt; Claire M Nightingale; Peter H Whincup; Ian Nm Day Journal: J Psychopharmacol Date: 2011-07 Impact factor: 4.153
Authors: Megan E Piper; Daniel M Bolt; Su-Young Kim; Sandra J Japuntich; Stevens S Smith; Jeff Niederdeppe; Dale S Cannon; Timothy B Baker Journal: J Abnorm Psychol Date: 2008-11
Authors: Dale S Cannon; Robin J Mermelstein; Tait R Medina; Oksana Pugach; Donald Hedeker; Robert B Weiss Journal: Nicotine Tob Res Date: 2015-11-05 Impact factor: 4.244
Authors: Emily Olfson; Joseph Bloom; Sarah Bertelsen; John P Budde; Naomi Breslau; Andrew Brooks; Robert Culverhouse; Grace Chan; Li-Shiun Chen; David Chorlian; Danielle M Dick; Howard J Edenberg; Sarah Hartz; Dorothy Hatsukami; Victor M Hesselbrock; Eric O Johnson; John R Kramer; Samuel Kuperman; Jacquelyn L Meyers; John Nurnberger; Bernice Porjesz; Nancy L Saccone; Marc A Schuckit; Jerry Stitzel; Jay A Tischfield; John P Rice; Alison Goate; Laura J Bierut Journal: Addict Biol Date: 2016-12-29 Impact factor: 4.280
Authors: James W Baurley; Christopher K Edlund; Carissa I Pardamean; David V Conti; Ruth Krasnow; Harold S Javitz; Hyman Hops; Gary E Swan; Neal L Benowitz; Andrew W Bergen Journal: Nicotine Tob Res Date: 2016-04-25 Impact factor: 4.244